Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies

, Paul Monagle, Anthonie W. A. Lensing*, Kirstin Thelen, Ida Martinelli, Christoph Male, Amparo Santamaria, Elena Samochatova, Riten Kumar, Susanne Holzhauer, Paola Saracco, Paolo Simioni, Jeremy Robertson, Gernot Grangl, Jacqueline Halton, Phillip Connor, Guy Young, Angelo C. Molinari, Ulrike Nowak-Goettl, Gili KenetStefanie Kapsa, Stefan Willmann, Akos F. Pap, Michael Becka, Teresa Twomey, Jan Beyer-Westendorf, Martin H. Prins, Dagmar Kubitza

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)E500-E509
Number of pages10
JournalThe Lancet Haematology
Volume6
Issue number10
DOIs
Publication statusPublished - Oct 2019

Keywords

  • DEEP-VEIN THROMBOSIS
  • REPORTED TREATMENT SATISFACTION
  • XA INHIBITOR RIVAROXABAN
  • ORAL RIVAROXABAN
  • ATRIAL-FIBRILLATION
  • STANDARD THERAPY
  • DEFINITION

Cite this

Monagle, Paul ; Lensing, Anthonie W. A. ; Thelen, Kirstin ; Martinelli, Ida ; Male, Christoph ; Santamaria, Amparo ; Samochatova, Elena ; Kumar, Riten ; Holzhauer, Susanne ; Saracco, Paola ; Simioni, Paolo ; Robertson, Jeremy ; Grangl, Gernot ; Halton, Jacqueline ; Connor, Phillip ; Young, Guy ; Molinari, Angelo C. ; Nowak-Goettl, Ulrike ; Kenet, Gili ; Kapsa, Stefanie ; Willmann, Stefan ; Pap, Akos F. ; Becka, Michael ; Twomey, Teresa ; Beyer-Westendorf, Jan ; Prins, Martin H. ; Kubitza, Dagmar. / Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr) : results from three multicentre, single-arm, phase 2 studies. In: The Lancet Haematology . 2019 ; Vol. 6, No. 10. pp. E500-E509.
@article{6f5e4a121223445fbd4ad546bede11b6,
title = "Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies",
keywords = "DEEP-VEIN THROMBOSIS, REPORTED TREATMENT SATISFACTION, XA INHIBITOR RIVAROXABAN, ORAL RIVAROXABAN, ATRIAL-FIBRILLATION, STANDARD THERAPY, DEFINITION",
author = "Paul Monagle and Lensing, {Anthonie W. A.} and Kirstin Thelen and Ida Martinelli and Christoph Male and Amparo Santamaria and Elena Samochatova and Riten Kumar and Susanne Holzhauer and Paola Saracco and Paolo Simioni and Jeremy Robertson and Gernot Grangl and Jacqueline Halton and Phillip Connor and Guy Young and Molinari, {Angelo C.} and Ulrike Nowak-Goettl and Gili Kenet and Stefanie Kapsa and Stefan Willmann and Pap, {Akos F.} and Michael Becka and Teresa Twomey and Jan Beyer-Westendorf and Prins, {Martin H.} and Dagmar Kubitza",
year = "2019",
month = "10",
doi = "10.1016/S2352-3026(19)30161-9",
language = "English",
volume = "6",
pages = "E500--E509",
journal = "The Lancet Haematology",
issn = "2352-3026",
publisher = "ELSEVIER SCI LTD",
number = "10",

}

Monagle, P, Lensing, AWA, Thelen, K, Martinelli, I, Male, C, Santamaria, A, Samochatova, E, Kumar, R, Holzhauer, S, Saracco, P, Simioni, P, Robertson, J, Grangl, G, Halton, J, Connor, P, Young, G, Molinari, AC, Nowak-Goettl, U, Kenet, G, Kapsa, S, Willmann, S, Pap, AF, Becka, M, Twomey, T, Beyer-Westendorf, J & Prins, MH & Kubitza, D 2019, 'Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies', The Lancet Haematology , vol. 6, no. 10, pp. E500-E509. https://doi.org/10.1016/S2352-3026(19)30161-9

Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr) : results from three multicentre, single-arm, phase 2 studies. /; Monagle, Paul; Lensing, Anthonie W. A.; Thelen, Kirstin; Martinelli, Ida; Male, Christoph; Santamaria, Amparo; Samochatova, Elena; Kumar, Riten; Holzhauer, Susanne; Saracco, Paola; Simioni, Paolo; Robertson, Jeremy; Grangl, Gernot; Halton, Jacqueline; Connor, Phillip; Young, Guy; Molinari, Angelo C.; Nowak-Goettl, Ulrike; Kenet, Gili; Kapsa, Stefanie; Willmann, Stefan; Pap, Akos F.; Becka, Michael; Twomey, Teresa; Beyer-Westendorf, Jan; Prins, Martin H.; Kubitza, Dagmar.

In: The Lancet Haematology , Vol. 6, No. 10, 10.2019, p. E500-E509.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr)

T2 - results from three multicentre, single-arm, phase 2 studies

AU - Monagle, Paul

AU - Lensing, Anthonie W. A.

AU - Thelen, Kirstin

AU - Martinelli, Ida

AU - Male, Christoph

AU - Santamaria, Amparo

AU - Samochatova, Elena

AU - Kumar, Riten

AU - Holzhauer, Susanne

AU - Saracco, Paola

AU - Simioni, Paolo

AU - Robertson, Jeremy

AU - Grangl, Gernot

AU - Halton, Jacqueline

AU - Connor, Phillip

AU - Young, Guy

AU - Molinari, Angelo C.

AU - Nowak-Goettl, Ulrike

AU - Kenet, Gili

AU - Kapsa, Stefanie

AU - Willmann, Stefan

AU - Pap, Akos F.

AU - Becka, Michael

AU - Twomey, Teresa

AU - Beyer-Westendorf, Jan

AU - Prins, Martin H.

AU - Kubitza, Dagmar

PY - 2019/10

Y1 - 2019/10

KW - DEEP-VEIN THROMBOSIS

KW - REPORTED TREATMENT SATISFACTION

KW - XA INHIBITOR RIVAROXABAN

KW - ORAL RIVAROXABAN

KW - ATRIAL-FIBRILLATION

KW - STANDARD THERAPY

KW - DEFINITION

U2 - 10.1016/S2352-3026(19)30161-9

DO - 10.1016/S2352-3026(19)30161-9

M3 - Article

VL - 6

SP - E500-E509

JO - The Lancet Haematology

JF - The Lancet Haematology

SN - 2352-3026

IS - 10

ER -